In a letter dated November 5 that the FDA posted to its site today, the Food and Drug Administration noted that it inspected Colgate-Palmolive’s (CL) drug manufacturing facility, Tom’s of Maine, in Sanford, Maine, from May 7 to 22 and summarized the “significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals” that the agency found. In late morning trading following the posting of the warning letter, shares of Colgate-Palmolive are down $1.56, or nearly 2%, to $93.07.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Colgate Palmolive put volume heavy and directionally bearish
- Coinbase initiated, Edwards Lifesciences upgraded: Wall Street’s top analyst cal
- Colgate-Palmolive price target lowered to $110 from $115 at TD Cowen
- Colgate-Palmolive price target lowered to $92 from $100 at Wells Fargo
- Colgate-Palmolive downgraded to Hold from Buy at Stifel